Pharmacological properties
Pharmacodynamics. antiallergic agent, mast cell membrane stabilizer, inhibits the release of histamine, leukotrienes and other biologically active substances from stem cells. This mechanism of action is universal in relation to all mucous membranes of the human body (including bronchi, nasal cavity, eyes, intestines). inhibits the migration of neutrophils, eosinophils, monocytes. prevents allergic reactions of immediate and delayed type after penetration of allergens.
Pharmacokinetics. After intranasal administration, 7% enters the general vasculature (1% can be swallowed). The drug is excreted from the body within 24 hours unchanged, in equal amounts with urine and bile.
Indication
Prevention and treatment of acute and chronic seasonal or year-round allergic rhinitis, hay fever.
Application
Immediately before use, hold the bottle with the drug in the palm of your hand to warm it to body temperature. Before administering the drug, it is necessary to carefully clear the nose. When using the drug, hold the bottle vertically, with the nozzle upwards. Before use, remove the protective cap, then place the tip of the nozzle in the nasal passage, inject the drug with light pressure of the fingers. During injection, it is recommended to inhale slightly through the nose. After use, close the bottle with a protective cap.
One injection of Cromofarm spray contains 2 mg of sodium cromoglicate (2.7 drops of the drug solution).
Adults and children over 5 years of age: 1 spray into each nostril 3-4 times a day. If necessary, the frequency of use in adults can be increased to 6 times a day.
In seasonal allergic rhinitis, treatment should be started immediately after the first symptoms appear or used prophylactically before the patient's contact with a known allergen. After achieving a therapeutic effect, the intervals between doses of the drug may be gradually extended. Cancellation should be carried out gradually over 1 week. The duration of use depends on the type and severity of the disease.
Contraindication
Hypersensitivity to cromoglycic acid and other components of the drug; pregnancy and lactation, children under 5 years of age; severe renal and/or hepatic insufficiency; nasal polyps.
Side effects
Respiratory system disorders: irritation or burning of the nasal mucosa, frequent sneezing, cough, rhinorrhea, rarely - nosebleeds, mild dryness in the throat, stridor or difficulty breathing, cough, suffocation, ulceration of the nasal mucosa;
Immune system disorders: very rarely anaphylactic reactions, angioedema, difficulty swallowing, swelling of the face, lips, tongue or eyelids, arthralgia may occur;
Skin and subcutaneous tissue disorders: skin rash, urticaria, skin itching, rash;
gastrointestinal disorders: change in taste, dysphagia, nausea, abdominal pain;
neurological disorders: dizziness, headache, migraine;
cardiac disorders: decreased blood pressure;
others: lacrimation.
Special instructions
In acute inflammation and during exacerbation of the chronic process, the drug should be used in combination with antihistamines or corticosteroids. The patient should be warned about the need for regular use of the drug. In renal failure, functional parameters should be monitored; if necessary, the dose may be reduced.
Accidental ingestion of Cromofarm solution is safe. No special measures are required, except for medical supervision.
The drug should not be used if the integrity of the vial is broken, or if the solution becomes cloudy.
Use during pregnancy and breastfeeding. Sodium cromoglycate is excreted in breast milk in small quantities, so when using the drug during breastfeeding, the risk of harmful effects on young children is minimal or practically absent. However, the use of the drug during pregnancy, especially in the first trimester, or during breastfeeding is possible when, in the opinion of the doctor, the expected benefit to the mother outweighs the potential risk to the fetus or child.
The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Does not affect.
Children. Do not use in children under 5 years of age. Treatment of children over 5 years of age with the drug is possible only after consulting a doctor.
Interactions
There is no data on the negative drug interaction of sodium cromoglicate (in the form of a nasal spray) with other drugs. When including cromoglicate in therapy with antihistamines, β-adrenomimetics, glucocorticoids and theophylline, the dose of the latter may be reduced.
Overdose
Cases of overdose have not been established, but in case of overdose, increased adverse reactions are possible. Treatment is symptomatic.
Storage conditions
In a place protected from light at a temperature of 15-25 °C.
